209 results
8-K
EX-99.1
TPST
Tempest Therapeutics, Inc.
8 Aug 24
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
4:33pm
; changes in expected or existing competition; changes in the regulatory environment; and unexpected litigation or
other disputes. Other factors
424B5
TPST
Tempest Therapeutics, Inc.
20 Jun 24
Prospectus supplement for primary offering
8:32am
to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;
additions or departures … of key personnel;
significant lawsuits, including patent or stockholder litigation;
S-10
if securities or industry analysts do not publish research
8-K
EX-1.1
TPST
Tempest Therapeutics, Inc.
20 Jun 24
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
8:13am
or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation … offered or sold or at common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or expense arises
8-K
EX-99.1
4bexce48q xst9zi3
9 May 24
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
4:25pm
8-K
EX-99.1
ld587l 8pqfr8
19 Mar 24
Tempest Reports Year End 2023 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.1
mme7dk0
8 Nov 23
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
5:18pm
8-K
EX-99.1
62tov cfdsu
10 Aug 23
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
4:27pm
8-K
EX-99.1
uj9hjxfeaqhr
10 May 23
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
4:21pm
8-K
9udma
31 Mar 23
Other Events
5:07pm
8-K
EX-10.1
6heim5k
29 Dec 22
Entry into a Material Definitive Agreement
4:06pm